- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
It was a record setting day on Wall Street Tuesday.
12/23/14 - 04:36 PM EST
The biotech stock's shares fell again Tuesday following the news of Express Scripts' exclusive deal with AbbVie. Here's what analysts said about Gilead.
12/23/14 - 01:48 PM EST
Gilead Pharmaceuticals (GILD) plunged over 14% on Monday, making it TheStreet's Move of the Day.
12/22/14 - 05:32 PM EST
These Achillion results aren't great because the speed at which drugs kill the hepatitis C virus matters. Slower-acting drugs leave patients vulnerable to viral rebound or relapse.
12/22/14 - 11:36 AM EST
AbbVie strikes an exclusive deal with Express Scripts to exclusively distribute AbbVie's hepatitis C therapy. Here's what analysts said.
12/22/14 - 11:20 AM EST
Which biotech and pharmaceuticals stocks should investors buy in 2015? JPMorgan named six companies with the best investment cases as part of its top U.S. stocks picks for 2015.
12/22/14 - 08:23 AM EST
The power to control drug prices in the U.S. now has shifted firmly to cost-cutting insurance carriers and pharmacy benefit managers and away from biotech and drug companies.
12/22/14 - 06:14 AM EST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
12/19/14 - 10:46 AM EST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
12/19/14 - 09:02 AM EST
Wednesday's session featured some good moves and technical set-ups, particularly in biotech and technology.
12/18/14 - 01:44 PM EST
Congrats to David Schenkein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
12/18/14 - 10:01 AM EST
- Tickers in this article:
Companies involved in mining, petroleum exploration, agribusiness, biotechnology and tourism may benefit.
12/17/14 - 03:43 PM EST